Kiniksa Pharmaceuticals (NASDAQ:KNSA) is set to give its latest quarterly earnings report on Tuesday, 2026-02-24. Here's what investors need to know before the announcement.

Analysts estimate that Kiniksa Pharmaceuticals will report an earnings per share (EPS) of $0.35.

Investors in Kiniksa Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Performance in Previous Earnings

The company's EPS missed by $0.12 in the last quarter, leading to a 5.2% drop in the share price on the following day.

Here's a look at Kiniksa Pharmaceuticals's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	0.35	0.21	0.28	0.13
EPS Actual	0.23	0.23	0.11	-0.12
Price Change %	-5.00	-1.00	4.00	0.00

Market Performance of Kiniksa Pharmaceuticals's Stock

Shares of Kiniksa Pharmaceuticals were trading at $47.77 as of February 20. Over the last 52-week period, shares are up 143.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Insights Shared by Analysts on Kiniksa Pharmaceuticals

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Kiniksa Pharmaceuticals.

Analysts have given Kiniksa Pharmaceuticals a total of ratings, with the consensus rating being . The average one-year price target is $, indicating a potential .

To track all earnings releases for Kiniksa Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.